课题基金 / 基金详情

Targeted therapy of mesothelin expressing cancers using

Targeted therapy of mesothelin expressing cancers using
使用间皮素表达癌症的靶向治疗
批准号:
7291852
负责人:
RAFFIT HASSAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

RAFFIT HASSAN的其他基金

相似基金

相关文献

中文摘要
翻译
我们的临床研究重点是靶向治疗表达间充质蛋白的癌症。间皮蛋白是一种40 kDa的细胞表面糖蛋白,存在于胸膜、心包和腹膜内的正常间皮细胞上。它在间皮瘤、卵巢癌和胰腺癌患者中高度表达。我们目前正在进行一项针对间皮蛋白表达癌症患者的抗间皮蛋白免疫毒素SS1P的I期临床试验。迄今共治疗了31例患者(腹膜间皮瘤10例,胸膜间皮瘤6例,腹股沟间皮瘤1例,卵巢癌12例,胰腺癌2例)。SS1P隔日静脉注射×3次最大耐受量为45微克/公斤/剂量。为了预防胸膜炎,这是较高剂量SS1P的剂量限制毒性,我们将用泼尼松对患者进行预治疗,以确定这是否会允许剂量进一步增加。在接受治疗的30名可评估患者中,15人病情稳定,2人轻微反应,2人腹水消退,11人病情进展。1例卵巢癌腹水和盆腔腹水完全消退,持续6个月,1例腹膜间皮瘤腹水完全消退,持续3年以上。我们目前正在计划SS1P的第二阶段临床试验,用于恶性间皮瘤和其他表达间皮素的恶性肿瘤患者。 除了利用间充质蛋白作为癌症治疗的靶点外,我们还在评估血清间充质蛋白作为表达间充质蛋白肿瘤的肿瘤标志物的作用。在与LMB的其他成员以及实验室医学部的Alan Remaley博士的合作下,我们已经开发出一种用于测量血清间皮蛋白的ELISA。我们的结果显示,在大多数间皮瘤和卵巢癌患者中,间皮蛋白水平升高。我们的结果还表明,腹膜间皮瘤患者手术后血清间皮素水平下降。这些结果表明,血清间皮质素可以作为一种有价值的肿瘤标记物,用于跟踪和监测肿瘤表达间皮质素的患者的治疗反应。 我们将使用这种酶联免疫吸附试验来检测正在接受组蛋白去乙酰酶抑制剂SAHA的III期随机、双盲、安慰剂对照试验的胸膜间皮瘤患者的血清间皮素水平。这项由默克公司进行的多机构试验,预计将有660名患者参加,这将使我们能够确定间皮林作为间皮瘤的肿瘤标志物的效用。血清间皮蛋白水平将与肿瘤分期、肿瘤负担、组织学以及对SAHA的反应相关。
英文摘要
Our clinical research is focused on targeted therapy of mesothelin expressing cancers. Mesothelin is a 40-kDa cell surface glycoprotein that is present on normal mesothelial cells lining the pleura, pericardium and peritoneum. It is highly expressed in patients with mesothelioma and ovarian and pancreatic cancers. We are currently conducting a Phase I clinical trial of the anti-mesothelin immunotoxin SS1P in patients with mesothelin expressing cancers. A total of 31 patients (10 peritoneal mesothelioma; 6 pleural mesothelioma; 1 inguinal mesothelioma; 12 ovarian cancer; 2 pancreatic cancer) have been treated to date. The maximum tolerated dose of SS1P given intravenously every other day x 3 doses is 45 micrograms/kg/dose. To prevent pleuritis that was the dose limiting toxicity at higher doses of SS1P, we will be pre-treating patients with prednisone to determine if this will allow further dose escalation. Of the 30 evaluable patients treated, 15 had stable disease; 2 had minor response; 2 had resolution of ascites and 11 had progressive disease. One patient with ovarian cancer had complete resolution of abdominal and pelvic ascites lasting 6 months; 1 patient with peritoneal mesothelioma has had complete resolution of abdominal ascites lasting more than 3 years. We are currently planning phase II clinical trials of SS1P for patients with malignant mesothelioma and other mesothelin expressing malignancies. In addition to utilizing mesothelin as a target for cancer therapy we are evaluating serum mesothelin as a tumor marker for mesothelin expressing tumors. In collaboration with other members of the LMB, as well as Dr. Alan Remaley of the Department of Laboratory Medicine we have developed an ELISA to measure serum mesothelin. Our results show that mesothelin levels are elevated in majority of patients with mesothelioma and ovarian cancer. Our results also show that serum mesothelin levels fall after surgery in patients with peritoneal mesothelioma. These results suggest that serum mesothelin can be a valuable tumor marker to follow and monitor treatment response in patients whose tumors express mesothelin. We will use this ELISA to measure serum mesothelin levels in patients with pleural mesothelioma being treated on a Phase III, randomized, double-blind, placebo-controlled trial of the histone deacetylase inhibitor SAHA. This multi-institutional trial being conducted by Merck Inc. and expected to accrue 660 patients will allow us to determine the utility of mesothelin as a tumor marker in mesothelioma. Serum mesothelin levels will be correlated with tumor stage, tumor burden, and histology as well as response to SAHA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical evaluation of an anti-mesothelin immunotoxin
Immunotherapy for Malignant Mesothelioma and Lung Cancer
  • 批准号:
    10702415
  • 项目类别:
  • 资助金额:
    $201.88万
  • 财政年份:
    --
  • 负责人:
    RAFFIT HASSAN
  • 依托单位:
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
Immunotherapy for Malignant Mesothelioma
国内基金
海外基金
慢性炎症诱发骨丢失的机制及外泌体靶向治疗策略研究
  • 批准号:
    82370889
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    傅德皓
  • 依托单位:
抑制FGF19/FGFR4信号通路促进肺鳞癌细胞焦亡及免疫增效的机制研究
  • 批准号:
    32100565
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李凡
  • 依托单位:
黑色素瘤中PPM1D介导的去磷酸化修饰调控NRAS蛋白功能的机制研究
  • 批准号:
    32100579
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    尹成骞
  • 依托单位:
间充质干细胞通过CD73/CD39/腺苷-PI3K/Akt-Nrf2信号轴调节CD4+IL-10+IFN-γ+T细胞分化减弱GVHD机制研究
  • 批准号:
    32070781
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    栾希英
  • 依托单位: